Drug Profile
Research programme: influenza virus vaccines - Johnson and Johnson/CureVac
Alternative Names: RNActive® influenza vaccine - Johnson and Johnson/CureVacLatest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator CureVac
- Developer CureVac; Johnson & Johnson
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Influenza virus infections (Prevention) in Germany (Intradermal)
- 27 Mar 2023 Discontinued - Preclinical for Influenza virus infections (Prevention) in Netherlands (Intradermal)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Germany (Intradermal, Injection)